On 16 June, the primary investigators of the UK’s RECOVERY trial announced that the commonly used, low-price corticosteroid dexamethasone has proven to be a potentially life-saving new treatment option for those critically ill with Covid-19 and requiring respiratory support.
It’s low cost, wide availability and easy administration is what makes dexamethasone’s success in Covid-19 patients on oxygen or ventilators so special.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The UK Government’s chief scientific adviser Sir Patrick Vallance stated: “It is particularly exciting as this is an inexpensive, widely available medicine. This is a ground-breaking development in our fight against the disease.”
Read the full article here.
